Sep 21, 2025, 07:47
WFH: Hemophilia Innovations from Factor Therapy to Gene Therapy
World Federation of Hemophilia (WFH) shared on X:
”Hemophilia has led rare disease innovation—from factor therapy to Gene Therapy—thanks to decades of advocacy and investment. But continued progress depends on sustained support. The future of treatment access is in our hands.
Read more in Blood Advances:”
Find similar posts on Hemostasis Today.
-
Jan 5, 2026, 22:01Sifat Jubaira on Key Differences in Red Cell Indices
-
Jan 5, 2026, 20:03Alan Nurden: One of The Best Articles That I Have Read in 2025
-
Jan 5, 2026, 18:16Bartosz Hudzik on Hemocompatibility in HeartMate 3 LVAD: Progress and Persistent Challenges
-
Jan 5, 2026, 15:33Mona Ahmed on Why Some Calcified Nodules Trigger ACS and Others Do Not
-
Jan 5, 2026, 14:17Abdul Mannan – VWF:RCo for Diagnosing von Willebrand Disease: That Test Might Be Failing Your Patients
-
Jan 5, 2026, 13:57Ewang Yemi: CAD is Real and Dangerous – Keep Your Heart Beating
-
Jan 5, 2026, 13:42Dr. Martha Boeckenfeld Shares VetiGel Creation Experiment: How A 17-Year-Old Mixed Algae in a Small Hidden Lab
-
Jan 5, 2026, 12:55Chokri Ben Lamine Explains Washed PRBCs!
-
Jan 5, 2026, 12:30ASH: Be Part of The Next Cohort of Hematology Quality Improvement Leaders